Altor BioScience

Hing C. Wong, Ph.D. - President & Chief Executive Officer

Dr. Wong has served as the President and Chief Executive Officer of Altor BioScience since its inception in August 2002. Dr. Wong has over twenty-three years’ experience working in the biotechnology industry. In 1996, Dr. Wong founded Sunol Molecular Corporation and served as the Chairman and Chief Executive Officer until Sunol’s assets were sold in 2005. At Sunol, Dr. Wong directed R&D operations including the development of four recombinant antibodies from initial research characterization through clinical testing in patients. Dr. Wong has also been leading corporate operations including financing, acquisitions, technology licensing, and formation of new companies via spin-off and joint venture. Dr. Wong formerly serves on the board of directors of Biosynexus Inc., a biotechnology company formed as part of a joint venture between Sunol and Virion Systems Inc., and a member of the Board of Trustees of the Rumbaugh-Goodwin Institute of Cancer Research Inc. Prior to founding Sunol, Dr. Wong served as the Director of the Biology Skills Center at the Dade Division of Baxter International Inc. From 1983 to 1992, Dr. Wong was with Cetus/Chiron Corporation where he held various scientific and managerial positions including Director of the Department of Microbial Genetics. He is the Principal Investigator of NIH grants, an inventor of numerous patents and an author of many scientific publications in peer-reviewed journals. Dr. Wong received his Ph.D. degree from the University of Massachusetts at Amherst.

Peter Rhode, Ph.D. - Vice President, Research & Development

Dr. Rhode has served as the Vice President of Research and Development of Altor since its inception. Dr. Rhode was among the team of scientists that formed Sunol Molecular in 1996 where he served as Research Director developing therapeutic approaches for treating human autoimmune diseases. Dr. Rhode has made significant contributions toward the design and advancement of Altor’s proprietary technologies and currently directs the Company’s efforts to develop these technologies for therapeutic application. He is an inventor on over 20 issued patents and an author of numerous scientific publications. From 1991 to 1996, Dr. Rhode was with the Dade Division of Baxter International Inc. Dr. Rhode received his Ph.D. degree in Biochemistry at the University of Wisconsin, Madison.

Dean P. Taylor, Ph.D., Chief Business Development Officer

Dr. Taylor joined Altor in early 2009. He was most recently Vice President of Business Development at Accera, Inc. in Broomfield, CO. He previously served as a consultant to Altor Bioscience and GMP Companies and an advisor to Tequesta Marine Biosciences. Formerly the Chief Operating Officer for Sunol Molecular Corp. until May 2005, he was involved in the spin-out of Altor from Sunol in 2002 and the deals that resulted in transfer of Sunol assets to Caprion and Tanox. Dr. Taylor joined Sunol in 1997 as Vice President of Business Development, managing partnership development and intellectual property. He led pre-clinical and clinical development of Sunol’s lead products as Sr. VP of Corporate Affairs from 2001, and was promoted to COO in 2003. Dr. Taylor began his career at SmithKline & French Laboratories, joining in 1979 and becoming Assistant Director of the Molecular Genetics Department in 1985 where he headed a laboratory that successfully developed novel expression systems for production of recombinant proteins for drug discovery and development. In 1989, Dr. Taylor joined Panlabs (now part of MDS Pharmaceutical Services), becoming Director of Biotechnology, Americas/Asia in 1991. His experiences at Panlabs included the management of more than a dozen multi-year yield improvement and molecular biology projects, as well as providing a leading role in representing Panlabs’ contract services in Asia. Dr. Taylor received his Bachelor of Science degree in Microbiology from the University of Washington, Seattle, a Ph.D. degree in Molecular Biology from the University of Wisconsin, Madison, for research on the control of plasmid copy number and continued with postdoctoral training at Stanford University in the area of replication and incompatibility of cloning vectors.

Jeffrey S. Weber, M.D., Ph.D., Consulting Medical Director

Dr. Weber was engaged by Altor BioScience as a consulting Medical Director in January 2007. He is currently Professor of Oncology and Medicine and Head of the Melanoma Center of Excellence at H. Lee Moffitt Cancer Center in Tampa, Florida. Dr. Weber was the Chief of Medicine at the USC/Norris Cancer Hospital in Los Angeles, California and Chief of Medical Oncology at the USC’s Keck School of Medicine. Dr. Weber is board certified in Internal Medicine and Medical Oncology. Dr. Weber was the recipient of the Bob Chandler Courage Award form the University of Southern California in 1998, the K24 Mid-Career Mentor Award from NIH in the years 2000-2004, and the Best Doctors in America Award in the years 2004-2007. He serves in many study sections for NCI and is a member of the Editorial Boards of Clinical Cancer Research, Human Gene Therapy and Journal of Immunotherapy. He is also a reviewer for Blood, Cancer, Cancer Gene Therapy, Cancer Research, Journal of Clinical Investigation, Journal of Clinical Oncology, Journal of Immunology and New England Journal of Medicine. Dr. Weber is an author of numerous scientific publications in peer-reviewed journals and a Principal Investigator of NCI grants. Dr. Weber is a graduate of New York University Medical School. He also earned a Ph.D. in molecular cell biology from Rockefeller University in New York.

Bee-Yau Huang, M.S., Director, Clinical Development

Ms. Huang received her Bachelor of Science degree from the Department of Zoology, National Taiwan University in 1976 and her Master of Science degree from the Department of Computer and Information Sciences, University of Massachusetts at Amherst in 1980. Her graduate work focused on artificial intelligence programming. She also assumed the position of Database Administration for the School of Administration from 1978 to 1980. In 1980, Ms. Huang joined the Frank Russell Company, a premier investment company in Tacoma, Washington as a computer graphics specialist. In 1983, Ms. Hang joined the Data Access Storage Division of International Business Machines in San Jose, California, as a System Development Programmer and was promoted to the Staff Programmer position in 1987. She joined Baxter International Inc. in 1992 as Computer Specialist where she established computer modeling capabilities for protein engineering for R&D division. In 1994, she assumed a group leader position for project management and planning. In 1996, she joined Sunol and served as the Director of Operations and Corporate Controller. In 2003, she served as the Director of Clinical Development to implement and to oversee the Phase IIa Acute Lung Injury/Acute Respiratory Distress Syndrome clinical trial with Sunol-CH36 until the program was successfully sold to Tanox Inc. She joined Altor in 2006 and serves as Director of Project Management and Clinical Development. She is also the Treasurer of Altor.

Pierre-Andre Chavaillaz, Ph.D., Director, Product Development

Dr. Chavaillaz was a member of the scientific team Sunol Molecular Corporation in 1996, where his research focused on recombinant antibody production, particularly the generation of recombinant mammalian cell lines for large-scale production of human-mouse chimeric antibodies as well as fully human antibodies. He joined Altor in 2005, where he is responsible for managing development of the production cell line for Altor’s single chain, soluble T-cell receptor proteins. His earlier research was conducted at Baxter Healthcare and Dade International, where he generated several human-mouse heteromyeloma cell lines for use in monoclonal antibody production and he was a collaborator on three issued patents for novel proteins. Dr. Chavaillaz holds a Master’s Degree in organic chemistry from the University of Fribourg in Switzerland, where he also earned his doctorate in biochemistry. He obtained post-doctoral training at the University of Sherbrooke, Quebec, Canada, and at the University of Bern, Switzerland.

Scientific Staff

Altor has a highly trained scientific staff, two thirds of whom hold degrees at the doctoral level. The team worked together on TCR- and MHC-based technologies (many for over 10 years) at Sunol Molecular Corporation prior to the formation of Altor BioScience. The staff has extensive experience in biotechnology, and their collective expertise covers molecular biology, molecular and conventional immunology, transgenic animal development, cell biology, recombinant protein production, drug screening technologies and protein chemistry. As a result of the quality and experience of this staff, Altor is well positioned to conduct sophisticated applied research and development in drug discovery.

Board of Directors

Fred Middleton. M.B.A.
- Chairman of the Board of Directors, Altor BioScience Corporation
- Managing Director, Sanderling Ventures
- Former Chief Financial Officer, Genentech, Inc.
- Founder, Morgan Stanley Ventures
Fred Middleton has over 30 years of experience in the biotechnology and biomedical industries in both corporate operating management and as an institutional venture capital investor. At Sanderling, he has over time served as an investor, management team member and director in over 25 new biomedical ventures built in Sanderling’s venture investment portfolios since 1988. Recently, he has played an active role as Chairman, CEO or Director of a number of current Sanderling portfolio companies, currently including Stereotaxis (NASDAQ: STXS), CardioNet (NASDAQ: BEAT), Novocell, Cylene Pharmaceuticals, Endocyte, Pacira, LineaGen, Inc., and Actimis.
Mr. Middleton began his career as a consultant for McKinsey & Company's San Francisco office from 1973 to 1975. He subsequently worked as a Vice President in corporate development for Chase Bank in New York.
In 1978, Mr. Middleton joined Bob Swanson and Herb Boyer, the founders of biotechnology pioneer Genentech, Inc., as the third member of the original management team, where he served in various capacities, including Vice President of Finance, Administration, Corporate Development, Chief Financial Officer, and as President of Genentech Development Corporation. While at Genentech, Mr. Middleton successfully completed over $200 million in corporate partnering and institutional funding transactions, including managing the Company's successful IPO in 1980.
In 1984, Mr. Middleton founded Morgan Stanley Ventures, an affiliate of Morgan Stanley, serving as Managing General Partner of an institutional fund funding technology investments. Mr. Middleton joined Sanderling in 1987 as a General Partner, to raise and manage institutional funds to invest in early stage biomedical companies.
Mr. Middleton earned his B.S. in chemistry from the Massachusetts Institute of Technology in 1971 and an M.B.A with distinction from Harvard Business School in 1973. In 2007, he was elected to serve as a member of the M.I.T. Corporation.
C. Boyden Gray, J.D.
- Member, Board of Directors, Altor BioScience Corporation
- Former US Ambassador to the European Union & Special Envoy
- Former Partner, Wilmer Cutler Pickering Hale & Dorr
Mr. Gray served most recently as the Special Envoy for European Affairs and Special Envoy for Eurasian Energy at the U.S. mission to the EU. He was previously U.S. Ambassor to the EU. Prior to that, he was a partner with the law firm of Wilmer Cutler Pickering Hale and Dorr. He served as White House Counsel to President George H. W. Bush. He graduated from Harvard University in 1964, served as a sergeant in the US Marine Corps Reserve and attended law school at the University of North Carolina, graduating in 1968. He clerked for Chief Justice Earl Warren for one term before joining Wilmer Cutler & Pickering in 1969, becoming partner in 1976. Gray left the firm in 1981 to serve as legal counsel for Vice President George Bush, later served as Director of the Office of Transition Counsel for the Bush transition team, and as Counsel to President Bush from 1989-1993.
Adam Waldman, J.D.
- Co-Founder & President, The Endeavor Group
- Director, Indian River Brewing Company and i5 Investments
- Founding board member, Friends of the Global Fight
- Director, the Center for Global Development (CGD)
- Former Senior Telecommunications Counsel to Assistant Attorney General Joel Klein at the U.S. Department of Justice.
Mr. Waldman is the founder and President of the Endeavor Group, where he oversees the firm’s work and maintains direct involvement with Endeavor clients regarding their transactional and regulatory affairs. During the past decade he has advised on a broad range of business transactions and has solved a myriad of complex legal and regulatory challenges. He also has architected ground-breaking public/private partnerships in global development and guided the launch and scale of several leading global health advocacy organizations. Prior to founding Endeavor, Mr. Waldman served as Senior Counselor to Assistant Attorney General Joel I. Klein at the U.S. Department of Justice. Prior to his government service, Mr. Waldman was a corporate lawyer in the Washington, D.C. office of Wilmer, Cutler & Pickering, where he executed domestic and international mergers and acquisitions. Mr. Waldman earned his J.D. from the American University Law School, where he was Editor of the Law Review, and a B.A. from Rollins College.
Hing C. Wong, Ph.D.
President & CEO, Altor BioScience Corporation
Former Chairman of the Board & CEO - Sunol Molecular Corp.
Former Director - Biosynexus Inc.
Former Member of Board of Trustees - Rumbaugh-Goodwin Institute of Cancer Research Inc.

See BIO above

Clinical Advisory Board

Altor currently has two Clinical Advisory Boards, one for the ALI/ARDS trials and the other for melanoma:

Clinical/Scientific Advisory Board for ALI/ARDS:

R. Scott Harris, M.D., Assistant Professor of Medicine, Pulmonary and Critical Care Unit, Massachusetts General Hospital, Boston, MA
Peter E. Morris, M.D., Associate Professor, Pulmonary, Critical Care, Allergy, and Immunologic Medicine, Wake Forest University Baptist Medical Center, Winston-Salem, NC
Steven M Opal, M.D., Professor of Medicine, Infectious Disease Division, Brown University School of Medicine, and Chief of Infectious Diseases, Memorial Hospital of Rhode Island, Pawtucket, RI
Jay S. Steingrub, M.D., Associate Chair of Research, Department of Medicine, Professor of Medicine, Tufts University School of Medicine, Co-Director, Adult Critical Care Program, Director, Critical Care Research, Baystate Medical Center, Springfield, MA
Arthur P. Wheeler, M.D., Associate Professor, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN

Clinical/Scientific Advisory Board for Melanoma:

Adil Daud, M.D., Clinical Professor, Dept. of Medicine (Hematology/Oncology), Director, Melanoma Clinical Research, Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA
Robert L. Ferris, M.D., Ph.D., Professor and Chief, Division of Head and Neck Surgery, Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Lynn Feun, M.D., Professor of Medicine, Sylvester Comprehensive Cancer Research Center, University of Miami Hospital and Clinics, Miami, FL
Patrick Hwu, M.D., Chair and Professor, Department of Melanoma Medical Oncology, M.D. Anderson Cancer Center and Professor at The University of Texas Graduate School of Biomedical Sciences, Houston, TX
Kim A. Margolin, M.D., Professor, Division of Oncology, University of Washington School of Medicine and Member, Division of Clinical Research, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, Seattle, WA
Jeffrey S. Weber, M.D., Ph.D., Consulting Medical Director, Altor and Professor of Oncology and Medicine and Director, Donald A. Adam Comprehensive Melanoma Research Center, H. Lee Moffitt Cancer Center, Tampa, FL
Jedd D. Wolchok, M.D., Ph.D., Associate Attending Physician, Associate Director of the Ludwig Center for Cancer Immunotherapy, and Director of Immunotherapy Clinical Trials, Memorial Sloan-Kettering Cancer Center, New York, NY

Back